Kiniksa Pharmaceuticals International, plc (KNSA)
Nasdaq: KNSA · Pharmaceutical Preparations · London · filing with the SEC since 2018
Grade7.2
◀ Past 7.8● Present 7.7▶ Future 5.7
Who owns Kiniksa Pharmaceuticals International, plc
As filed with the SECHolders of 5% or more
5
Fmr LLC holds 14.8% of CLASS A COMMON STOCK, as its SCHEDULE 13G/A filed May 6, 2026 says.
Directors and officers
19
report now, of 27 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · CLASS A COMMON STOCK · 10.6% in Mar 6, 2026
Rubric Capital Management LP
SCHEDULE 13G/A · filed Feb 13, 2026 · Class A Ordinary Shares, nominal value $0.000273235 per share · 9.24% in Jul 9, 2025
Julian C. Baker
SCHEDULE 13D/A · filed May 26, 2026 · Class A Ordinary Shares, nominal value $0.000273235 per share
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock · 1% in Jul 17, 2025
Tang Capital Management, LLC
SCHEDULE 13G · filed Apr 4, 2025 · Class A Ordinary Shares, nominal value $0.000273235 per share
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 7.04% in Oct 31, 2025
Fairmount Funds Management LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Class A Ordinary Shares, nominal value $0.000273235 per share · reported falling below 5%
What KNSA reports owning in othersstakes of 5% or more, and other ties
6 subsidiaries in 5 countries, from the list filed with the 10-K filed Feb 24, 2026.
Insider tradesForm 4
89sales
0purchases
88sales on a scheduled plan
8people selling
$122Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Patel Sanj K | CHAIRMAN & CEO | 28 | $81.1M | 28 | 0 | $0 |
| Paolini John F. | CHIEF MEDICAL OFFICER | 15 | $13.9M | 15 | 0 | $0 |
| Moat Ross | CHIEF OPERATING OFFICER | 13 | $9.8M | 13 | 0 | $0 |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | 11 | $8.9M | 11 | 0 | $0 |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | 10 | $5.2M | 10 | 0 | $0 |
| Quart Barry D | director | 8 | $2.7M | 8 | 0 | $0 |
| Tessari Eben | CHIEF STRATEGY OFFICER | 4 | $1.0M | 4 | 0 | $0 |
| Cole G Bradley | director | 1 | $300,000 | 0 | 0 | $0 |